Enoxaparin for primary thromboprophylaxis in symptomatic outpatients with COVID-19 (OVID): a randomised, open-label, parallel-group, multicentre, phase 3 trial

BACKGROUND: COVID-19 is a viral prothrombotic respiratory infection. Heparins exert antithrombotic and anti-inflammatory effects, and might have antiviral properties. We aimed to investigate whether thromboprophylaxis with enoxaparin would prevent untoward hospitalisation and death in symptomatic, b...

Descripción completa

Detalles Bibliográficos
Autores principales: Barco, Stefano, Voci, Davide, Held, Ulrike, Sebastian, Tim, Bingisser, Roland, Colucci, Giuseppe, Duerschmied, Daniel, Frenk, André, Gerber, Bernhard, Götschi, Andrea, Konstantinides, Stavros V, Mach, François, Robert-Ebadi, Helia, Rosemann, Thomas, Simon, Noemi R, Spechbach, Hervé, Spirk, David, Stortecky, Stefan, Vaisnora, Lukas, Righini, Marc, Kucher, Nils
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9243568/
https://www.ncbi.nlm.nih.gov/pubmed/35779558
http://dx.doi.org/10.1016/S2352-3026(22)00175-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9243568/
https://www.ncbi.nlm.nih.gov/pubmed/35779558
http://dx.doi.org/10.1016/S2352-3026(22)00175-2

Ejemplares similares